Abstract | BACKGROUND: METHODS: This prospective, multicenter, non-interventional study investigated the efficacy and safety of tigecycline in hospitalized, severely ill patients with complicated intra-abdominal infections (cIAI) and/or complicated skin and soft tissue infections (cSSTI). Documentation included diagnosis, clinical findings, Acute Physiology and Chronic Health Evaluation II score, laboratory assessments, surgery, clinical outcomes, and adverse events. RESULTS: Six hundred and fifty-six patients (mean Acute Physiology and Chronic Health Evaluation II score 19.1) with cIAI (41%), cSSTI (16%), multiple infection sites (13%) and/or other severe infections (31%) received tigecycline - 51% as monotherapy - due to failure of previous antibiotics (55%) or since resistant pathogens were suspected or proven (45%); clinical cure/improvement rates were 75, 82, 76 and 67% for cIAI, cSSTI, other severe infections and multiple infection sites, respectively. Drug-related adverse events occurred in 6.7% of patients. CONCLUSIONS: The efficacy and safety of tigecycline was demonstrated in a population of severely ill patients with complicated infections.
|
Authors | Christian Eckmann, Wolfgang R Heizmann, Eva Leitner, Christof von Eiff, Klaus-Friedrich Bodmann |
Journal | Chemotherapy
(Chemotherapy)
Vol. 57
Issue 4
Pg. 275-84
( 2011)
ISSN: 1421-9794 [Electronic] Switzerland |
PMID | 21778715
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 S. Karger AG, Basel. |
Chemical References |
- Anti-Bacterial Agents
- Tigecycline
- Minocycline
|
Topics |
- Aged
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Escherichia coli
(pathogenicity)
- Female
- Germany
- Humans
- Infections
(complications, drug therapy, microbiology)
- Male
- Middle Aged
- Minocycline
(adverse effects, analogs & derivatives, therapeutic use)
- Prospective Studies
- Severity of Illness Index
- Soft Tissue Infections
(drug therapy)
- Staphylococcal Skin Infections
(drug therapy)
- Staphylococcus aureus
(pathogenicity)
- Tigecycline
- Treatment Outcome
|